Treat-and-extend dosing of intravitreal anti-VEGF agents in neovascular age-related macular degeneration: a meta-analysis

Less Is More

“…Further studies of TAE protocols with drugs such as ranibizumab and aflibercept have demonstrated noninferior functional and anatomical outcomes, with reduced treatment burden. 16,[31][32][33] Treat-and-Extend With Ranibizumab: CANTREAT CANTREAT (Canadian Treat-and-Extend Analysis Trial) and its open-label extension study evaluated the ability to extend ranibizumab 0.5-mg dosing beyond 4 weeks to intervals of up to 12 weeks. [34][35][36] The TAE protocol was to extend from injections every 4 weeks by 2-week intervals until a maximum of 12 weeks if disease remained stable.…”

A colorimetric immunoassay for the detection of human vascular endothelial growth factor 165 (VEGF165) based on anti-VEGF-iron oxide nanoparticle conjugation

“…Particularly, it participates in a variety of physiological angiogenic processes, including wound healing [ 6 ], female reproduction cycle [ 7 ], embryogenesis [ 8 ], neural development [ 9 ], bone formation [ 10 ], and hematopoiesis [ 11 ] in healthy adults. However, under certain circumstances, the overexpression of VEGF is well correlated with rheumatoid arthritis [ 12 ], Parkinson’s disease [ 13 ], psoriasis [ 14 ], and several ocular diseases [ 15 , 16 ], while VEGF activity continues physiologically normal during vascular development. Besides, VEGF has also been widely described as a major tumor angiogenic factor in many tumor types [ 17 , 18 ].…”